Aurobindo Pharma News

Stay tuned here for latest updates on Indian markets, including BSE Sensex, NSE Nifty, Indian rupee and MCX gold.

Overseas, European stock markets were trading slightly higher while most Asian stocks rose in anticipation of US inflation data and earnings from some of the large banks.

Homegrown pharmaceuticals firm Aurobindo Pharma expects to launch 19 approved products that have an addressable market of USD 6.8 billion in the US in the next three quarters.

Shares of Aurobindo Pharma surged over 2 percent today after the firm got final approval from USFDA to manufacture and market its generic Naproxen Sodium tablets used for treatment of osteoporosis.

Aurobindo Pharma has received final nod from the US health regulator to manufacture and market its generic Naproxen Sodium tablets used for the treatment of osteoporosis in postmenopausal wome

Aurobindo Pharma on Thursday said it has received shareholders' nod to raise up to USD 600 million (around Rs 3,974 crore) via issue of securities.      

The company expects to launch the product by fourth quarter of the current fiscal.

 Aurobindo Pharma today said it has received final approval from USFDA to manufacture and market generic version of Risedronate Sodium tablets, used in the treatment of Osteoporosis, in the American market.

Aurobindo Pharma will seek approval from its shareholders for an enabling resolution to raise up to USD 600 million (around Rs 3,974 crore) via issue of securities.

Aurobindo Pharma has rreceived final approval from the US Food and Drug Administration to launch Tramadol Hydrochloride extended-release tablets in the US maket.

The company has several levers to gain traction with a robust business model, a large differentiated product portfolio that addresses six key therapeutic areas and a growing presence in over 150 countries.

Recently, the drug firm had said that it intends to invest up to Rs 900 crore this fiscal on various activities including capacity expansion, clinical trials and product filings.

The approval by the USFDA is for strengths of 100 mg/5 ml and 200 mg/5 ml and the product is ready for launch, Aurobindo Pharma said in a statement.

Aurobindo Pharma has divested stake in its Australian subsidiary to Eris Pharma for an undisclosed amount to focus on the US, European and emerging markets.

Shares of Plethico Pharmaceuticals zoomed 20 percent Thursday after reaching settlement with Aurobindo Pharma related to the acquisition of US-based Natrol.

Drug major Aurobindo Pharma has received final approval from the US health regulator to manufacture and market Atracurium Besylate injections in the American market.

Aurobindo Pharma on Thursday said Plethico will pay it USD 23.3 million to settle a dispute related to the acquisition of US-based Natrol.

Pharmaceutical majors Glenmark and Aurobindo's foreign investment proposals, worth Rs 4,187 crore, were approved by the government Tuesday.

Drug firm Aurobindo Pharma has received tentative approval from the US health regulator USFDA for its generic Lacosamide tablets used in treatment of partial seizures in epilepsy patients.

Indian companies have raised over USD 4 billion (Rs 27,000 crore) from Qualified Institutional Placement (QIP) of shares so far in the current fiscal, while plans are underway to garner further funds worth an estimated USD 3 billion through this route.